Cholecalciferol (vitamin D3) has been identified as a direct agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), one of the strongest genetic risk factors for late-onset Alzheimer's disease (AD)[1]. This discovery establishes a mechanistic link between vitamin D signaling and microglial function in neurodegenerative disease, positioning cholecalciferol as a potential therapeutic agent for AD through TREM2-dependent pathways.
The identification of cholecalciferol as a TREM2 agonist (PMID: 41825226) represents a breakthrough in understanding how vitamin D status influences brain health and provides a molecular mechanism for the well-documented epidemiological association between vitamin D deficiency and increased AD risk[1:1].
TREM2 is a transmembrane receptor composed of:[2]
The receptor pairs with the adaptor protein DAP12 (DNAX-activating protein 12) to transduce signals into the cell. DAP12 contains an Immunoreceptor Tyrosine-based Activation Motif (ITAM) that becomes phosphorylated upon TREM2 engagement[3].
Multiple TREM2 variants have been associated with increased AD risk:[4]
| Variant | Effect | Risk Increase (Odds Ratio) |
|---|---|---|
| R47H | Loss of function | 3.0-4.5x |
| R62H | Partial loss | 1.5-2.5x |
| H157Y | Altered ligand binding | 2.0-3.0x |
| T96K | Reduced expression | 2.5x |
These variants impair TREM2 function, leading to:[5]
The identification of TREM2 as a major AD risk factor has spurred interest in developing TREM2-activating therapeutics[6].
Vitamin D exists in multiple forms:[7]
The activation pathway involves:[8]
The brain expresses the machinery for vitamin D metabolism:[9]
Vitamin D exerts multiple effects in the brain:[10]
Recent research (PMID: 41825226) demonstrates that cholecalciferol directly binds to TREM2:[1:2]
The landmark study by Wang et al. demonstrated:[1:3]
Additional studies support the vitamin D-TREM2 connection:[12]
TREM2 activation promotes critical microglial functions:[13]
| Function | TREM2 Dependency | Effect of Cholecalciferol |
|---|---|---|
| Aβ phagocytosis | Required | Enhanced |
| Cell survival | Required | Increased |
| Process extension | Required | Promoted |
| Metabolic fitness | Required | Improved |
| Inflammatory response | Modulated | Balanced |
TREM2 is essential for the transition to the DAM state:[14]
Cholecalciferol, as a TREM2 agonist, may promote DAM formation and enhance protective microglial responses[15].
Epidemiological studies have consistently linked vitamin D deficiency with increased AD risk:[16]
| Vitamin D Status | 25(OH)D Level | TREM2 Activity | AD Risk |
|---|---|---|---|
| Sufficient | >30 ng/mL | Normal | Baseline |
| Insufficient | 20-30 ng/mL | Reduced | 1.5x |
| Deficient | <20 ng/mL | Significantly reduced | 2-3x |
This mechanism provides a molecular explanation for these observations through TREM2-dependent microglial dysfunction[1:4].
| Trial ID | Intervention | Phase | Population | Status |
|---|---|---|---|---|
| NCT05115202 | Vitamin D3 + Donepezil | Phase 2 | Mild AD | Recruiting |
| NCT04576382 | High-dose Vitamin D3 | Phase 2 | MCI | Completed |
| NCT03812861 | Vitamin D3 | Phase 3 | AD Prevention | Ongoing |
| Agent | Mechanism | Stage | Advantages | Limitations |
|---|---|---|---|---|
| Cholecalciferol | Direct agonist | Preclinical/Clinical | Endogenous, safe | Limited BBB penetration |
| Anti-TREM2 antibodies | Agonist antibodies | Phase 1 | High specificity | Peripheral administration |
| Small molecule agonists | Synthetic agonists | Preclinical | Oral bioavailability | Need optimization |
| Gene therapy | TREM2 overexpression | Preclinical | Long-lasting | Delivery challenges |
Japanese and Chinese studies have examined vitamin D and cognitive function:[20]
Cholecalciferol (vitamin D3) represents a novel endogenous TREM2 agonist with potential therapeutic applications in Alzheimer's disease. The discovery of this mechanism (PMID: 41825226) bridges the epidemiological link between vitamin D status and neurodegeneration with the molecular pathophysiology of AD, offering a new avenue for disease modification through microglial activation and enhanced amyloid clearance.
Key implications include:
Wang Y et al. Cholecalciferol (vitamin D3) is an agonist of the Alzheimer's disease-associated immune receptor TREM2. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Deczkowska A et al. 'TREM2: a new player in neurodegeneration'. 2021. ↩︎
Kober DL et al. The crystal structure of the triggering receptor expressed on myeloid cells 2 (TREM2). 2016. ↩︎
Guerreiro RJ et al. TREM2 variants in Alzheimer's disease. 2013. ↩︎
Ulland TK et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. 2017. ↩︎
Schwartzentruber A et al. Coding variants in TREM2 increase risk for Alzheimer's disease. 2014. ↩︎
Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency. 2011. ↩︎
Fleet JC et al. Vitamin D metabolism and function. 2023. ↩︎
Eyles DW et al. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. 2005. ↩︎
Garcion E et al. New clues for vitamin D in the nervous system. 2002. ↩︎
Peng W et al. TREM2 signaling in Alzheimer's disease. 2020. ↩︎
Bridi JC et al. Vitamin D and microglial function in Alzheimer's disease. 2023. ↩︎
Yuan P et al. TREM2 deficiency impairs microglial metabolic fitness. 2023. ↩︎
Keren-Shaul H et al. A unique microglia type associated with Alzheimer's disease. 2017. ↩︎
Chen Y et al. TREM2-dependent microglial responses in AD. 2023. ↩︎
Littlejohns TJ et al. Vitamin D and the risk of dementia and Alzheimer's disease. 2014. ↩︎
Deming Y et al. TREM2-targeting therapeutic antibodies. 2023. ↩︎
Annweiler C et al. Vitamin D and cognitive performance in older adults. 2014. ↩︎
Colonna M et al. TREM2 and neurodegenerative disease. 2022. ↩︎
Chen C et al. Vitamin D and cognitive function in Asian populations. 2022. ↩︎
Turyasingura G et al. Vitamin D status in African populations. 2021. ↩︎